Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y101D + Gemcitabine + Nab-Paclitaxel in First-line Advanced Pancreatic Cancer
NCT06266143Phase 2Completed
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Jan 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of Y101D in pancreatic cancer (PC), sponsored by Wuhan YZY Biopharma Co., Ltd.. Started Feb 2023; status: completed.
02
Drugs
Y101D
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06266143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06266143.